249 related articles for article (PubMed ID: 32154655)
1. JAK2V617F mutation prevalence on Chilean adults suffering from primary mesenteric and portal venous thromboses.
González-Montero J; Del Valle-Batalla L; Castillo-Astorga R; Marín Valdés A; Conte Lanza G
Int J Lab Hematol; 2020 Jun; 42(3):331-334. PubMed ID: 32154655
[TBL] [Abstract][Full Text] [Related]
2. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis.
Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R
J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900
[TBL] [Abstract][Full Text] [Related]
3. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients.
Pardanani A; Lasho TL; Hussein K; Schwager SM; Finke CM; Pruthi RK; Tefferi A
Mayo Clin Proc; 2008 Apr; 83(4):457-9. PubMed ID: 18380991
[TBL] [Abstract][Full Text] [Related]
4. Portal vein thrombosis patients harboring JAK2V617F have poor long-term outcomes despite anticoagulation.
Naymagon L; Tremblay D; Zubizarreta N; Moshier E; Schiano T; Mascarenhas J
J Thromb Thrombolysis; 2020 Oct; 50(3):652-660. PubMed ID: 32034618
[TBL] [Abstract][Full Text] [Related]
5. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis.
Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW
Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of overt myeloproliferative neoplasms and JAK2 V617F mutation in Korean patients with splanchnic vein thrombosis.
Yoo EH; Jang JH; Park KJ; Gwak GY; Kim HJ; Kim SH; Kim DK
Int J Lab Hematol; 2011 Oct; 33(5):471-6. PubMed ID: 21435189
[TBL] [Abstract][Full Text] [Related]
7. JAK2V617F mutation in patients with splanchnic vein thrombosis.
Xavier SG; Gadelha T; Pimenta G; Eugenio AM; Ribeiro DD; Gomes FM; Bonamino M; Zalcberg IR; Spector N
Dig Dis Sci; 2010 Jun; 55(6):1770-7. PubMed ID: 19690956
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of JAK2V617F mutation in deep venous thrombosis patients and its clinical significance as a thrombophilic risk factor: Indian perspective.
Singh N; Sharma A; Sazawal S; Ahuja A; Upadhyay A; Mahapatra M; Saxena R
Clin Appl Thromb Hemost; 2015 Sep; 21(6):579-83. PubMed ID: 25804613
[TBL] [Abstract][Full Text] [Related]
9. [Visceral Vein Thrombosis of Myeloproliferative Neoplasm --Review].
Zhang X; Yang J; Hao HL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1627-1630. PubMed ID: 36208278
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis.
Li M; De Stefano V; Song T; Zhou X; Guo Z; Zhu J; Qi X
Thromb Res; 2018 Jul; 167():96-103. PubMed ID: 29803161
[TBL] [Abstract][Full Text] [Related]
11. Erythrocytes from patients with myeloproliferative neoplasms and splanchnic venous thrombosis show greater expression of Lu/BCAM.
Novitzky-Basso I; Spring F; Anstee D; Tripathi D; Chen F
Int J Lab Hematol; 2018 Aug; 40(4):473-477. PubMed ID: 29756283
[TBL] [Abstract][Full Text] [Related]
12. JAK2V617F mutation in patients with portal vein thrombosis.
Bayraktar Y; Harmanci O; Büyükasik Y; Shorbagi AI; Sungur AH; Boylu CA; Gürgey A; Balkanci F
Dig Dis Sci; 2008 Oct; 53(10):2778-83. PubMed ID: 18343999
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study.
Qi X; Zhang C; Han G; Zhang W; He C; Yin Z; Liu Z; Bai W; Li R; Bai M; Yang Z; Wu K; Fan D
J Gastroenterol Hepatol; 2012 Jun; 27(6):1036-43. PubMed ID: 22142461
[TBL] [Abstract][Full Text] [Related]
14. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.
Qi X; Yang Z; Bai M; Shi X; Han G; Fan D
Aliment Pharmacol Ther; 2011 May; 33(10):1087-103. PubMed ID: 21395632
[TBL] [Abstract][Full Text] [Related]
15. Relevance of the JAK2V617F mutation in patients with deep vein thrombosis of the leg.
Lauw MN; Bus EW; van Wulfften Palthe AF; Coppens M; Homburg CH; Middeldorp S; van der Schoot CE; Koene HR; Biemond BJ
Ann Hematol; 2012 Jan; 91(1):103-7. PubMed ID: 21484303
[TBL] [Abstract][Full Text] [Related]
16. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation.
Colaizzo D; Amitrano L; Guardascione MA; Tiscia GL; D'Andrea G; Longo VA; Grandone E; Margaglione M
Thromb Res; 2013 Aug; 132(2):e99-e104. PubMed ID: 23916380
[TBL] [Abstract][Full Text] [Related]
17. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
De Stefano V; Qi X; Betti S; Rossi E
Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
[TBL] [Abstract][Full Text] [Related]
18. PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and Prothrombin 20210A in Splanchnic Vein Thrombosis: Analysis of Individual Patient Data From Three Prospective Studies.
Pasta L; Pasta F; D'Amico M
J Clin Exp Hepatol; 2016 Mar; 6(1):10-4. PubMed ID: 27194890
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
Basquiera AL; Tabares AH; Soria N; Salguero M; Ryser R; García JJ
Medicina (B Aires); 2011; 71(4):313-6. PubMed ID: 21893442
[TBL] [Abstract][Full Text] [Related]
20. JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis?
Dhiman P; Saxena P
Case Rep Hematol; 2015; 2015():373490. PubMed ID: 25878908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]